Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative
Retrieved on:
Thursday, June 2, 2022
Health, FDA, Medical Devices, Diabetes, Clinical Trials, Research, Science, Insulin analog, Company, Research, Knowledge, Prediabetes, Pharmacokinetics, Pharmacology, Physician, FDA, Insulin, Biosimilar, Diabetes, Obesity, Clinical trial, Insulin lispro, Drug development, Civica Rx, AP, Safety, Insulin aspart, Pancreas, Pharmaceutical industry, Insulin glargine, Civica, Profil
Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
Key Points:
- Civica, Inc. (Civica, Civica Rx) today announced the selection of Profil, Neuss, Germany, as its clinical trial partner to support the development of its affordable insulins.
- Profil has conducted over 30 biosimilar insulin trials and is the leading clinical research organization for studies related to diabetes.
- With its extensive experience and quality track record, Profil is the ideal clinical trial partner for Civica.
- More information on Civica and its affordable insulin initiative, including commentary from partners and a fact sheet, can be found at https://civicainsulin.org .